Contributions of NeutralNikolai

Contributions by NeutralNikolai, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 327 edits includes activity predating the current log.

1. 04:32, 11 Jun 2026 (diff | hist) Contraindications of incretin therapy 4,993 ±0 m attribute the boxed-warning statement to the regulator that issued it
2. 12:20, 6 Feb 2026 (diff | hist) Talk:Liraglutide 885 +130 /* Should the article say liraglutide is obsolete? */ reply
3. 08:50, 27 Jan 2026 (diff | hist) Talk:Purity claim inflation 822 +70 /* Title implies bad faith */ reply
4. 09:30, 26 Jan 2026 (diff | hist) Talk:Purity claim inflation 400 +162 /* Title implies bad faith */ new section
5. 10:14, 18 Jan 2026 (diff | hist) Talk:GLP-1 receptor agonist 959 +170 /* Should class-level cardiovascular benefit be claimed? */ reply
6. 18:10, 31 Dec 2025 (diff | hist) Active pharmaceutical ingredient 4,569 ±0 fix a broken wikilink
7. 21:01, 20 Nov 2025 (diff | hist) Cagrilintide 4,256 ±0 expand §Material sold under the name
8. 08:20, 10 Oct 2025 (diff | hist) Insulin syringe unit conversion 6,290 ±0 m expand §Mass per unit at common concentrations
9. 09:28, 22 Mar 2025 (diff | hist) GLP-1 receptor agonist 9,254 ±0 state which salt form the mass in the infobox refers to
10. 12:31, 29 Dec 2024 (diff | hist) Survodutide 3,325 ±0 move the trade-name history out of the lead and into §Regulatory history
11. 22:03, 11 Nov 2024 (diff | hist) TRIUMPH trial programme 2,837 +357 m add the year of publication to each trial in the list